Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

pembrolizumab 36Cyclophosphamide 24Nivolumab 23Ipilimumab 22aldesleukin 19Interleukin-2 15fludarabine 14Specimen Handling 12Dacarbazine 11fludarabine phosphate 10Magnetic Resonance Spectroscopy 10Temozolomide 9Radiosurgery 9Biopsy 9cemiplimab 8Paclitaxel 8dabrafenib 5binimetinib 5Vemurafenib 5Radiotherapy 5Carboplatin 5trametinib 4sargramostim 4encorafenib 4avelumab 4Pemetrexed 4Leucovorin 4Fluorouracil 4Cisplatin 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × ontuxizumab × Dermatologic × Clear all
NCT01335009 2021-09-01

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Eisai Inc.

Phase 2 Completed
76 enrolled 13 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡